News | February 18, 2009

NIH $7.5M Grant to Fund Imaging for Cancer Detection, Monitoring

February 17, 2009 – The National Institutes of Health have given UCSD’s Rebecca and John Moores Cancer Center a $7.5 million grant to develop new methods for detecting cancer and monitoring its treatment at the newly established In Vivo Cellular and Molecular Imaging Center.
“We want to develop diagnostic tools that define the cancer at its earliest stage, not just whether it is there, but its characteristics,” said Robert Mattrey, M.D., co-principal investigator of the project and radiology professor at the UCSD School of Medicine.
Along with pharmacology, chemistry and biochemistry professor — and recent Nobel laureate — Roger Tsien, Mattrey will lead a project to improve strategies for detecting enzymes called matrix metalloproteinases, which aggressively break down tissue and enable cancers to spread. The research team is developing imaging tools for conducting ultrasounds that will help detect enzymes in prostate and breast cancers.
Mattrey said that clearly determining the aggressiveness of a cancer will likely influence the treatment decisions of both doctors and patients.
In another project, co-principal investigator and professor of radiology David Vera, Ph.D., will collaborate with medicine professor Stephen Howell, M.D., to use nuclear imaging and ultrasounds in virtually tracking cancer cells and monitoring the effectiveness of an experimental, platinum-based chemotherapy drug.
“It’s difficult to know if a drug is reaching its molecular target,” Mattrey said. “It’s not just a matter of knowing that the drug reaches the tumor, but also if it was able to inhibit or stop the chemical reaction that it was designed to do.”
A portion of the grant will also fund a study led by assistant professor of pathology Dwayne Stupack, Ph.D., involving the use of nanoparticles to detect changes in the blood vessels associated with tumors. Stupack hopes to develop an imaging system that will expose tumors in their earliest stages.

Source: The Guardian, University of California, San Diego

For more information:

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.